NovoCure Ltd

This Summary highlights certain information included in this Proxy Statement. This Summary does not contain all of the information that you should consider prior to voting. Please review the complete Proxy Statement and the Annual Report that accompanies the Proxy Statement for additional information.

2026 ANNUAL MEETING OF SHAREHOLDERS

VOTING MATTERS AND BOARD RECOMMENDATIONS

GENERAL INFORMATION

DIRECTOR NOMINEES

You have the opportunity to vote on the election of the following director nominees whose terms of office are expiring, and in the case of Mr. Leonard, who is being nominated for the first time. Additional information regarding each director nominee’s experience, skills and qualifications to serve as a member of our Board can be found in the Proxy Statement under Proposal 1 – Election of Directors. All of our directors are being elected for a one-year term at the 2026 annual general meeting of shareholders.

BOARD HIGHLIGHTS

The statistics below relate to our current directors, including nominees:

•73% of our Board members are independent

•Average age of directors is 60

•Average tenure of directors is 9.7 years

•27% of our Board members identify as female

•Highly qualified directors reflect broad mix of business backgrounds, skills and experiences

•73% of directors have international experience

•45% of directors have experience as a public company Chief Executive Officer ("CEO") or executive chair in the past five years

The table below provides certain highlights of the composition of our Board members and nominees as of the record date, with categories as set forth by Nasdaq Listing Rule 5606:

CORPORATE GOVERNANCE HIGHLIGHTS

•Separate Executive Chairman of the Board and Chief Executive Officer positions

•Strong Lead Independent Director position

•Three fully independent Board committees

•Executive session of independent directors and committee members held at each regularly-scheduled Board meeting and committee meeting

•Frequent Board and committee meetings to ensure awareness and alignment

◦Five Board meetings in 2025

◦17 standing committee meetings in 2025

•Directors attended 100% of Board and committee meetings held in 2025

•Annual Board and committee self-assessments and discussions with individual directors

•Strong clawback and anti-hedging/anti-pledging policies

•Senior executives do not receive tax gross-ups on severance or change in control benefits

•Significant share ownership requirements for directors and senior executives

•Our Board and its committees have an active role in risk oversight

2025 CORPORATE ACHIEVEMENTS

Increased adoption of Tumor Treating Fields ("TTFields") therapy

•As of December 31, 2025, 4,620 active patients were using Optune Gio® and Optune Lua®, an increase of 12% from year-end 2024.

•In 2025, 7,035 total prescriptions were received, an increase of 9% compared to 2024.

•Received CE Mark for the use of Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") concurrent with immune checkpoint inhibitor or docetaxel who have progressed on or after a platinum-based regimen. Following receipt of CE Mark, Novocure received local registration and launched Optune Lua for the treatment of NSCLC in Germany.

•Received approval from Japan's Ministry of Health, Labour and Welfare for the use of Optune Lua concurrent with PD-1/PD-L1 inhibitor for the treatment of adult patients with unresectable advanced or recurrent NSCLC who have progressed on or after platinum-based chemotherapy.

•Received a positive coverage determination from Spain's Ministry of Health for the use of Optune Gio to treat adult patients with newly diagnosed glioblastoma through the Spanish National Health System.

Advanced our clinical and product development pipelines

•Presented final data from the Phase 3 PANOVA-3 clinical trial, which explored the efficacy and safety of TTFields therapy together with gemcitabine and nab-paclitaxel for the treatment of unresectable, locally-advanced pancreatic cancer at the 2025 American Society of Clinical Oncology Annual Meeting. The PANOVA-3 trial met its primary endpoint as patients treated with TTFields therapy, gemcitabine and nab-paclitaxel exhibited a statistically significant extension in overall survival compared to patients treated with gemcitabine and nab-paclitaxel alone. The results of the PANOVA-3 trial were simultaneously published in the Journal of Clinical Oncology. Following publication of final data, a premarket approval application for the treatment of locally advanced pancreatic cancer was submitted to the U.S. Food and Drug Administration ("FDA").

•Presented final data from the Phase 3 METIS clinical trial, which explored the efficacy and safety of TTFields therapy together with best supportive care for the treatment of brain metastases from NSCLC following stereotactic radiosurgery at the 2025 American Society for Radiation Oncology Annual Meeting. The METIS trial met its primary endpoint as patients treated with TTFields therapy and best supportive care demonstrated a statistically significant extension in time to intracranial progression compared to patients treated with best supportive care alone. The results of the METIS trial were simultaneously published in the International Journal of Radiation Oncology Biology and Physics. Following publication of final data, a premarket approval application for the treatment of brain metastases from NSCLC was submitted to the FDA.

Developed and expanded our talent pool

•Announced the promotion of then President, Frank Leonard, to the role of Chief Executive Officer, effective December 1, 2025.

Created shareholder value by building a profitable business

•Generated $655 million in annual net revenues, an increase of 8% compared to 2024.

•Cash, cash equivalents and short-term investments totaling $448 million as of December 31, 2025.

EXECUTIVE COMPENSATION HIGHLIGHTS

The primary objectives of our executive compensation program are to attract, retain and motivate superior executive talent, to provide incentives that reward the achievement of performance goals that we believe support the enhancement of shareholder value and to align the executives’ interests with those of shareholders through long-term incentives. The following table highlights some of our executive compensation policies and practices, which are structured to drive performance and align our executives’ interests with our shareholders’ long-term interests: